Literature DB >> 19885924

Anaplastic thyroid cancer: Clinical outcomes with conformal radiotherapy.

Aarti Bhatia1, Archana Rao, Kie-Kian Ang, Adam S Garden, William H Morrison, David I Rosenthal, Douglas B Evans, Gary Clayman, Steven I Sherman, David L Schwartz.   

Abstract

BACKGROUND: The aim of this study was to review institutional outcomes for anaplastic thyroid cancer treated with conformal 3-dimensional radiotherapy (3DRT) or intensity-modulated radiotherapy (IMRT).
METHODS: In all, 53 consecutive patients were analyzed. Thirty-one (58%) patients were irradiated with curative intent. Median radiation dose was 55 Gray (Gy; range, 4-70 Gy). Thirteen (25%) patients received IMRT to a median 60 Gy (range, 39.9-69.0 Gy). Thirty-nine (74%) patients received chemotherapy with radiation.
RESULTS: The Kaplan-Meier estimate of overall survival (OS) at 1 year for definitively irradiated patients was 29%. Patients without distant metastases receiving >or=50 Gy had superior survival outcomes; 5 such patients had no evidence of disease at last follow-up. Use of IMRT versus 3DRT did not influence toxicity.
CONCLUSIONS: Outcomes for anaplastic thyroid cancer treated with 3DRT or IMRT remain equivalent to historical results. Healthy patients with localized disease who tolerate full dose irradiation can potentially enjoy prolonged survival. Biologically targeted radiosensitization merits prioritized investigation. (c) 2009 Wiley Periodicals, Inc.

Entities:  

Mesh:

Year:  2010        PMID: 19885924     DOI: 10.1002/hed.21257

Source DB:  PubMed          Journal:  Head Neck        ISSN: 1043-3074            Impact factor:   3.147


  31 in total

1.  Acute Tumor Lactate Perturbations as a Biomarker of Genotoxic Stress: Development of a Biochemical Model.

Authors:  Vlad C Sandulache; Yunyun Chen; Heath D Skinner; Tongtong Lu; Lei Feng; Laurence E Court; Jeffrey N Myers; Raymond E Meyn; Clifton D Fuller; James A Bankson; Stephen Y Lai
Journal:  Mol Cancer Ther       Date:  2015-09-16       Impact factor: 6.261

2.  Anaplastic Thyroid Carcinoma, Version 2.2015.

Authors:  Robert I Haddad; William M Lydiatt; Douglas W Ball; Naifa Lamki Busaidy; David Byrd; Glenda Callender; Paxton Dickson; Quan-Yang Duh; Hormoz Ehya; Megan Haymart; Carl Hoh; Jason P Hunt; Andrei Iagaru; Fouad Kandeel; Peter Kopp; Dominick M Lamonica; Judith C McCaffrey; Jeffrey F Moley; Lee Parks; Christopher D Raeburn; John A Ridge; Matthew D Ringel; Randall P Scheri; Jatin P Shah; Robert C Smallridge; Cord Sturgeon; Thomas N Wang; Lori J Wirth; Karin G Hoffmann; Miranda Hughes
Journal:  J Natl Compr Canc Netw       Date:  2015-09       Impact factor: 11.908

Review 3.  Anaplastic thyroid carcinoma: from clinicopathology to genetics and advanced therapies.

Authors:  Eleonora Molinaro; Cristina Romei; Agnese Biagini; Elena Sabini; Laura Agate; Salvatore Mazzeo; Gabriele Materazzi; Stefano Sellari-Franceschini; Alessandro Ribechini; Liborio Torregrossa; Fulvio Basolo; Paolo Vitti; Rossella Elisei
Journal:  Nat Rev Endocrinol       Date:  2017-07-14       Impact factor: 43.330

4.  Radiation therapy dose is associated with improved survival for unresected anaplastic thyroid carcinoma: Outcomes from the National Cancer Data Base.

Authors:  Todd A Pezzi; Abdallah S R Mohamed; Tommy Sheu; Pierre Blanchard; Vlad C Sandulache; Stephen Y Lai; Maria E Cabanillas; Michelle D Williams; Christopher M Pezzi; Charles Lu; Adam S Garden; William H Morrison; David I Rosenthal; Clifton D Fuller; G Brandon Gunn
Journal:  Cancer       Date:  2016-12-27       Impact factor: 6.860

5.  SEOM clinical guideline thyroid cancer (2019).

Authors:  E Gallardo; J Medina; J C Sánchez; A Viúdez; E Grande; I Porras; T Ramón Y Cajal; J Trigo; L Iglesias; J Capdevila
Journal:  Clin Transl Oncol       Date:  2020-01-31       Impact factor: 3.405

6.  Intensity-modulated radiation therapy use for the localized treatment of thyroid cancer: Nationwide practice patterns and outcomes.

Authors:  Paolo Goffredo; Timothy J Robinson; Linda M Youngwirth; Sanziana A Roman; Julie A Sosa
Journal:  Endocrine       Date:  2016-03-30       Impact factor: 3.633

7.  Survival advantage of chemoradiotherapy in anaplastic thyroid carcinoma: Propensity score matched analysis with multiple subgroups.

Authors:  Sibo Tian; Jeffrey M Switchenko; Teng Fei; Robert H Press; Mustafa Abugideiri; Nabil F Saba; Taofeek K Owonikoko; Amy Y Chen; Jonathan J Beitler; Walter J Curran; Theresa W Gillespie; Kristin A Higgins
Journal:  Head Neck       Date:  2019-12-16       Impact factor: 3.147

8.  Single agent nanoparticle for radiotherapy and radio-photothermal therapy in anaplastic thyroid cancer.

Authors:  Min Zhou; Yunyun Chen; Makoto Adachi; Xiaoxia Wen; Bill Erwin; Osama Mawlawi; Stephen Y Lai; Chun Li
Journal:  Biomaterials       Date:  2015-04-24       Impact factor: 12.479

Review 9.  Treatment of patients with anaplastic thyroid cancer during the last 20 years: whether any progress has been made?

Authors:  Vesna Bisof; Zoran Rakusic; Marija Despot
Journal:  Eur Arch Otorhinolaryngol       Date:  2014-06-03       Impact factor: 2.503

10.  Hypofractionated Radiotherapy Is Superior to Conventional Fractionation in an Orthotopic Model of Anaplastic Thyroid Cancer.

Authors:  Ayman Oweida; Andy Phan; Benjamin Vancourt; Tyler Robin; Mohammad K Hararah; Shilpa Bhatia; Dallin Milner; Shelby Lennon; Laura Pike; David Raben; Bryan Haugen; Nikita Pozdeyev; Rebecca Schweppe; Sana D Karam
Journal:  Thyroid       Date:  2018-06       Impact factor: 6.568

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.